BREAKING NEWS: Plus Therapeutics has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer. Full Press Release: https://bit.ly/PSTV_PR #braincancer #pediatriconcology #clinicaltrials
Recent Posts
- Plus Therapeutics CEO Highlights the Role of Precision Medicine in Cancer Treatment
- Leading Experts Discuss Leptomeningeal Metastases at SNO/ASCO CNS Metastases Conference
- Highlighting Leptomeningeal Metastases at SNO/ASCO 2025
- Understanding LM in Lung Cancer by Leptomeningeal Cancer Foundation
- Positive ReSPECT-LM Phase 1 Data at SNO/ASCO CNS Metastases Conference
Recent Comments